Reduced expression of SIRT2 in serous ovarian carcinoma promotes cell proliferation through disinhibition of CDK4 expression

被引:32
作者
Du, Yanhua [1 ,2 ]
Wu, Jun [3 ]
Zhang, Haiyan [1 ,2 ]
Li, Shaobo [3 ]
Sun, Hong [1 ,2 ]
机构
[1] Hosp Fudan Univ, Dept Gynecol Obstet & Gynecol, 419 Fangxie Rd, Shanghai 200011, Peoples R China
[2] Shanghai Key Lab Female Reprod Endocrine Related, Shanghai 200011, Peoples R China
[3] Shanghai Jiao Tong Univ, Sch Med, Fac Basic Med, Pathol Ctr,Shanghai Gen Hosp, Shanghai 200025, Peoples R China
关键词
silent information regulator 2 related enzyme 2; serous ovarian carcinoma; ovarian surface epithelium; FIGO staging; cyclin-dependent kinase 4; GASTRIC-CANCER CELLS; DEPENDENT KINASES; DOWN-REGULATION; GROWTH; INHIBITORS; TUMORIGENESIS; DEGRADATION; MELANOMA; SURVIVAL; TRIGGERS;
D O I
10.3892/mmr.2017.6183
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The silent information regulator 2 related enzyme 2 (SIRT2) has been reported to have an important role in tumorigenesis. Although two distinct effects of SIRT2 have recently been revealed, which explain opposing expression patterns in different types of cancer, the specific function of SIRT2 in ovarian cancer remains unknown. The present study investigated the expression of SIRT2 in serous ovarian carcinoma (SOC) and its pathogenic mechanism. It was observed that SIRT2 expression in SOC was significantly downregulated when compared with ovarian surface epithelium via western blot and immunohistochemistry. Statistical analysis revealed that attenuated expression of SIRT2 was associated with the International Federation of Gynecology and Obstetrics classification of ovarian cancer. Reduced SIRT2 expression during tumorigenesis failed to repress cyclin-dependent kinase 4 expression, which eventually led to accelerated cell proliferation. Furthermore, the wound healing assay and Transwell assay determined that reduced expression of SIRT2 promoted SOC cell migration and invasion. In conclusion, the results of the current study suggest that SIRT2 has a tumor-suppressor function in ovarian cells and it might be a viable target for further SOC treatment.
引用
收藏
页码:1638 / 1646
页数:9
相关论文
共 37 条
[1]  
[Anonymous], 2018, ANTI-CANCER DRUG, DOI [DOI 10.3322/caac.20115, DOI 10.1097/CAD.0000000000000617]
[2]   Emerging role of sirtuins on tumorigenesis: possible link between aging and cancer [J].
Cha, Yong I. ;
Kim, Hyun-Seok .
BMB REPORTS, 2013, 46 (09) :429-438
[3]   SIRT2 overexpression in hepatocellular carcinoma mediates epithelial to mesenchymal transition by protein kinase B/glycogen synthase kinase-3/-catenin signaling [J].
Chen, Juan ;
Chan, Anthony W. H. ;
To, Ka-Fai ;
Chen, Weixian ;
Zhang, Zhenzhen ;
Ren, Jihua ;
Song, Chunli ;
Cheung, Yue-Sun ;
Lai, Paul B. S. ;
Cheng, Suk-Hang ;
Ng, Margaret H. L. ;
Huang, Ailong ;
Ko, Ben C. B. .
HEPATOLOGY, 2013, 57 (06) :2287-2298
[4]   Trastuzumab Inhibits Growth of HER2-Negative Gastric Cancer Cells Through Gastrin-Initialized CCKBR Signaling [J].
Cui, Yan ;
Li, Shao-Bo ;
Peng, Xing-Chun ;
Wu, Jun ;
Fu, Guo-Hui .
DIGESTIVE DISEASES AND SCIENCES, 2015, 60 (12) :3631-3641
[5]   The role of sirtuin 2 activation by nicotinamide phosphoribosyltransferase in the aberrant proliferation and survival of myeloid leukemia cells [J].
Dan, Lan ;
Klimenkova, Olga ;
Klimiankou, Maxim ;
Klusman, Jan-Henning ;
van den Heuvel-Eibrink, Marry M. ;
Reinhardt, Dirk ;
Welte, Karl ;
Skokowa, Julia .
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2012, 97 (04) :551-559
[6]   Molecular Pathways: CDK4 Inhibitors for Cancer Therapy [J].
Dickson, Mark A. .
CLINICAL CANCER RESEARCH, 2014, 20 (13) :3379-3383
[7]   Proteomics-based identification of differentially expressed genes in human gliomas: down-regulation of SIRT2 gene [J].
Hiratsuka, M ;
Inoue, T ;
Toda, T ;
Kimura, N ;
Shirayoshi, Y ;
Kamitani, H ;
Watanabe, T ;
Ohama, E ;
Tahimic, CGT ;
Kurimasa, A ;
Oshimura, M .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2003, 309 (03) :558-566
[8]   A Novel Sirtuin 2 ( SIRT2) Inhibitor with p53-dependent Pro- apoptotic Activity in Non- small Cell Lung Cancer* [J].
Hoffmann, Gesine ;
Breitenbuecher, Frank ;
Schuler, Martin ;
Ehrenhofer-Murray, Ann E. .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2014, 289 (08) :5208-5216
[9]   Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase [J].
Imai, S ;
Armstrong, CM ;
Kaeberlein, M ;
Guarente, L .
NATURE, 2000, 403 (6771) :795-800
[10]   Emerging therapies: angiogenesis inhibitors for ovarian cancer [J].
Jackson, Amanda L. ;
Eisenhauer, Eric L. ;
Herzog, Thomas J. .
EXPERT OPINION ON EMERGING DRUGS, 2015, 20 (02) :331-346